Centre for Commercialisation of Regenerative Medicine Australia (CCRM)

12 BUSINESS VIEW OCEANIA VOLUME 4, ISSUE 7 Monash University, BioPlatforms Australia, Life Sciences Queensland, the BioMelbourne Network, Opyl, Cartherics, and the members of the Australian Alliance for Regenerative Medicine. Without the support of their network, Mr Tiziani says, CCRM Australia would not have experienced the same level of growth since their founding. CCRM Australia has identified six critical business units that will underpin future growth: Identifying Technologies, Incubating Technologies, Technology Research and Development, Manufacturing Technologies, Investing in Technologies, and Providing Specialist Advice. Looking ahead the organisation hopes to see the Australian regenerative medicine sector flourish. Mr Tiziani concludes, “We are spending more time providing insight into the Australian market and advising our network. We also educate those looking to enter the industry and connect them 20 YEARS OF EAR & HEARING RESEARCH, TREATMENT & EDUCATION Contact us to find out more & join the push to cure hearing loss. earscience.org.au | filippo.valente@earscience.org.au Inner Ear Organoid Clinical Research ClearDrum TREAT & CURE HEARING LOSS RESEARCH, INNOVATION & NOVEL TECHNOLOGIES TO With over $A25m in successful grants supporting our ground-breaking ear & hearing research, we translate research into hearing healthcare. Join us as we develop novel medical devices & treatments using gene therapy & nanotechnology to restore hearing & repair perforated eardrums. with the appropriate collaborators, researchers, resources etc., for their unique place in the system. We work with many start-ups in this way. We developed a consulting unit called CCRM Australia Clarity to solidify this role. CCRM Australia Clarity assists those in our industry through the provision of academic consulting reports- our expertise has lent us the ability to add an extra layer of insight that is very specific to the Australian market. We have record levels of investment in the sector for clinical trials, mostly by pharmaceutical companies and private investors, pushing even further after the COVID-19 pandemic.” CCRM PREFERRED VENDORS/PARTNERS n Tessara Therapeutics Pty Ltd www.tessaratherapeutics.com n Research Valet www.researchvalet.com.au n ACMD Bioengineering Facility www.acmd.org.au n StemCore www.stemcore.com.au | stem.core@uq.edu.au StemCore is a comprehensive human stem cell facility providing state-of-the-art research infrastructure to accelerate your life science research. StemCore provides expert service in generating custom induced pluripotent stem cells, provision of characterized embryonic stem cell lines, and production scale-up, targeted differentiation and genetic engineering to create bespoke stem cell tools. n Ear Science Institute Australia www.earscience.org.au